{"id":251224,"date":"2022-01-05T00:00:00","date_gmt":"2022-01-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0077-biopharma-benign-prostatic-hyperplasia-epidemiology-4\/"},"modified":"2026-04-26T11:19:47","modified_gmt":"2026-04-26T11:19:47","slug":"epidim0077-biopharma-benign-prostatic-hyperplasia-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0077-biopharma-benign-prostatic-hyperplasia-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Benign Prostatic Hyperplasia &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p class=\"text-align-left\">Clarivate Epidemiology&#8217;s coverage of <abbr title=\"benign prostatic hyperplasia\">BPH<\/abbr> comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of <abbr title=\"benign prostatic hyperplasia\">BPH<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p class=\"text-align-left\">Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.<\/p>\n<p class=\"text-align-left\">Clarivate Epidemiology&#8217;s <abbr title=\"benign prostatic hyperplasia\">BPH<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li class=\"text-align-left\">Of all people with <abbr title=\"benign prostatic hyperplasia\">BPH<\/abbr>, how many in each country across the developed world have been formally diagnosed?<\/li>\n<li class=\"text-align-left\">How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"benign prostatic hyperplasia\">BPH<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p class=\"text-align-left\">All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p class=\"text-align-left\">In total, Clarivate Epidemiology forecasts two <abbr title=\"benign prostatic hyperplasia\">BPH<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li class=\"text-align-left\">Total prevalent cases<\/li>\n<li class=\"text-align-left\">Diagnosed prevalent cases<\/li>\n<\/ul>\n<p class=\"text-align-left\">Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251224","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-benign-prostatic-hyperplasia","biopharma-product-epidemiology","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251224\/revisions"}],"predecessor-version":[{"id":283664,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251224\/revisions\/283664"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}